loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Venus Remedies Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Venus Remedies Ltd. 27 May 2026 12:11 PM

Q4FY26 & FY26 Result Announced for Venus Remedies Ltd.

Pharmaceuticals company Venus Remedies announced Q4FY26 & FY26 results

Standalone Financial Highlights:

  • Revenue from operations:
    • For Q4FY26, the company reported revenue of Rs 259.01 crore, reflecting a QoQ increase of 43.94% (vs Q3FY26: Rs 179.95 crore) and a YoY increase of 31.65% (vs Q4FY25: Rs 196.74 crore).
    • For FY26, the revenue from operations stood at Rs 768.73 crore, an annual growth of 19.28% compared to FY25 (Rs 644.47 crore).
  • Total Income:
    • Total income for Q4FY26 was Rs 263.64 crore, a QoQ growth of 44.57% (vs Q3FY26: Rs 182.36 crore) and a YoY growth of 31.29% (vs Q4FY25: Rs 200.81 crore).
    • For FY26, the total income was Rs 780.19 crore, up 18.17% from FY25 (Rs 660.24 crore).
  • Net Profit for the period:
    • The profit for Q4FY26 was Rs 43.45 crore, reflecting a QoQ increase of 74.36% (vs Q3FY26: Rs 24.92 crore) and a YoY increase of 193.78% (vs Q4FY25: Rs 14.79 crore).
    • For FY26, the net profit stood at Rs 99.31 crore, showing a growth of 89.00% compared to FY25 (Rs 52.55 crore).
  • Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 32.51, and For FY26, it was Rs 74.29.

Consolidated Financial Highlights:

  • Revenue from operations:
    • For Q4FY26, the consolidated revenue was Rs 259.40 crore, an increase of 43.90% QoQ (vs Q3FY26: Rs 180.26 crore) and 31.24% YoY (vs Q4FY25: Rs 197.66 crore).
    • For FY26, the consolidated revenue was Rs 769.60 crore, a growth of 17.88% compared to FY25 (Rs 652.89 crore).
  • Total Income:
    • Total consolidated income for Q4FY26 was Rs 264.35 crore, reflecting a QoQ increase of 44.63% (vs Q3FY26: Rs 182.78 crore) and a YoY increase of 31.04% (vs Q4FY25: Rs 201.73 crore).
    • For FY26, the total income was Rs 782.18 crore, compared to Rs 668.84 crore in FY25, an increase of 16.95%.
  • Net Profit (Attributable to Owners):
    • The consolidated net profit attributable to the owners of the company for Q4FY26 was Rs 40.68 crore, compared to Rs 32.39 crore in Q3FY26 (a QoQ increase of 25.59%) and Rs 11.67 crore in Q4FY25 (a YoY increase of 248.59%).
    • For FY26, the net profit attributable to owners was Rs 135.37 crore, an increase of 69.09% compared to FY25 (Rs 80.06 crore).
  • Earnings Per Share (EPS): The basic EPS for Q4FY26 was Rs 35.53, and For FY26, it was Rs 76.89.

Business Highlights:

  • Segment Performance: The company operates in a single reportable segment, namely "Pharmaceuticals".
  • Dividend: The Board has recommended a final dividend of Rs 10 per equity share (100% of face value of Rs 10 each) for FY26, subject to shareholder approval at the 37th Annual General Meeting.
  • Subsidiaries: The company has a wholly-owned subsidiary, Venus Pharma GmbH in Germany, and a step-down subsidiary, Venus Pharma Kft in Hungary.
  • Key Appointments: Mr. Saransh Chaudhary and Dr. Gurminder Singh Bedi were appointed as Additional Directors. Ms. Meenakshi Bishnoi was re-appointed as Chief Compliance Officer, and Mr. Kartik Chawda was appointed as Chief Information Officer & Head of IT, effective June 01, 2026.

Result PDF

Pharmaceuticals company Venus Remedies announced Q3FY26 results

  • Revenue: Rs 180.26 crore against Rs 176.52 crore during Q3FY25, change 2%.
  • PBT: Rs 33.47 crore against Rs 14.97 crore during Q3FY25, change 124%.
  • PAT: Rs 25.58 crore against Rs 19.6 crore during Q3FY25, change 31%.
  • EPS: 19.14 for Q3FY26.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app